Avenue Therapeutics Inc (ATXI)

Overview News Price History Why ATXI Down? Discussions Forecast Stock Split

Avenue Therapeutics Inc stock is currently priced at $0.13, with a 24-hour trading volume of 320.64K. It has seen a -3.42% decreased in the last 24 hours and a -18.75% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.1343 pivot point. If it approaches the $0.128 support level, significant changes may occur.

Avenue Therapeutics Inc Stock (ATXI) Financials Data

Avenue Therapeutics Inc (ATXI) Net Income 2024

ATXI net income (TTM) was -$10.38 million for the quarter ending December 31, 2023, a -192.15% decrease year-over-year.

Avenue Therapeutics Inc (ATXI) Cash Flow 2024

ATXI recorded a free cash flow (TTM) of -$12.45 million for the quarter ending December 31, 2023, a -63.92% decrease year-over-year.

Avenue Therapeutics Inc (ATXI) Earnings per Share 2024

ATXI earnings per share (TTM) was -$3.81 for the quarter ending December 31, 2023, a -36.58% decline year-over-year.

Avenue Therapeutics Inc Stock (ATXI) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Davidow Robert L	10% Owner	Dec 11 '23	Sale	0.14	264,000	36,960	681,000
Fortress Biotech, Inc.	10% Owner	Sep 08 '23	Buy	0.72	418,410	301,255	1,032,390
ROSENWALD LINDSAY A MD	Director	Sep 08 '23	Buy	0.72	348,675	251,046	354,318

Avenue Therapeutics Inc Stock (ATXI) Latest News

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

GlobeNewswire Inc.

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire Inc.

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

GlobeNewswire Inc.

Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

Benzinga

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

GlobeNewswire Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.